Corning Jereh Pharmaceutical-B (09966) subsidiary exercises warrants to subscribe for 4.7204 million Series E preferred shares issued by Pathos AI.

Zhitong Finance APP News, Alphamab Oncology-B (09966) announced that on October 23, 2026, the Company's wholly-owned subsidiary Alphamab Biopharmaceuticals (Hong Kong) Limited (the Subscriber), by delivering to Pathos AI an exercise notice under the warrant, together with the corresponding signature pages to its Fourth Amended and Restated Investor Rights Agreement, Fourth Amended and Restated Right of First Refusal and Co-Sale Agreement, and Fourth Amended and Restated Voting Agreement with Pathos AI, and completing payment of the exercise price, fully exercised the warrant.